Successful treatment of Listeria monocytogenes prosthetic valve endocarditis using rifampicin and benzylpenicillin in combination with valve replacement
- PMID: 28348807
- PMCID: PMC5361637
- DOI: 10.1099/jmmcr.0.005085
Successful treatment of Listeria monocytogenes prosthetic valve endocarditis using rifampicin and benzylpenicillin in combination with valve replacement
Abstract
Introduction.Listeria monocytogenes is an uncommon cause of prosthetic valve endocarditis (PVE). Recommended antimicrobial therapy typically includes intravenous β-lactams with or without synergistic aminoglycosides. In vitro studies have previously identified antagonism when rifampicin has been used in combination with β-lactams. However, in vivo data of rifampicin use are limited despite its enhanced anti-biofilm activity. Case presentation. A 63-year-old male presented with fever and back pain. L. monocytogenes bacteraemia and bioprosthetic aortic valve endocarditis was confirmed, along with spinal discitis and osteomyelitis. He was successfully treated with benzylpenicillin and rifampicin, in conjunction with valve replacement. Conclusion. Rifampicin remains an alternate agent to use, when there are contraindications to traditional aminoglycoside therapy. Further data on rifampicin use in L. monocytogenes PVE are awaited.
Keywords: Listeria; endocarditis; prosthetic valve; rifampicin.
Figures
References
-
- Fernández Guerrero ML, Rivas P, Rábago R, Núñez A, De Górgolas M, et al. Prosthetic valve endocarditis due to Listeria monocytogenes: report of two cases and reviews. Int J Infect Dis. 2004;8:97–102. - PubMed
-
- Baddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM., et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132:1435–1486. doi: 10.1161/CIR.0000000000000296. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources